Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer Portfolio News / By Karina Tin March 23, 2022 Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer Read More »
Ribon Therapeutics Initiates First-in-Human Phase 1 Clinical Study of RBN-3143 for the Treatment of Atopic Dermatitis Portfolio News / By Karina Tin March 22, 2022 Ribon Therapeutics Initiates First-in-Human Phase 1 Clinical Study of RBN-3143 for the Treatment of Atopic Dermatitis Read More »
NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022 Portfolio News / By Karina Tin March 21, 2022 NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022 Read More »
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update Portfolio News / By Karina Tin March 21, 2022 ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update Read More »
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Portfolio News / By Karina Tin March 16, 2022 eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Read More »
RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results Portfolio News / By Karina Tin March 10, 2022 RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results Read More »
NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting Portfolio News / By Karina Tin March 8, 2022 NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting Read More »
A2 Bio’s Activator-blocker CAR-T Cell Therapies Show Early Promise in Solid Cancers Portfolio News / By Karina Tin March 4, 2022 A2 Bio’s Activator-blocker CAR-T Cell Therapies Show Early Promise in Solid Cancers Read More »
A2 Bio Publishes Key Preclinical Findings Demonstrating Potential of Its Highly Selective Tmod™ Cell Therapy Platform to Revolutionize the Treatment of Solid Tumors in Select Patients Portfolio News / By Karina Tin March 2, 2022 A2 Bio Publishes Key Preclinical Findings Demonstrating Potential of Its Highly Selective Tmod™ Cell Therapy Platform to Revolutionize the Treatment of Solid Tumors in Select Patients Read More »
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results Portfolio News / By Karina Tin March 1, 2022 NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results Read More »
